SGLT2 inhibitors and cardiovascular outcomes in type 2 diabetes: VERTIS CV trial | GPnotebook TV

SGLT2 inhibitors and cardiovascular outcomes in type 2 diabetes: VERTIS CV trial

29 July 2020
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Dr Kevin Fernando summarises results from the cardiovascular outcomes trial of ertugliflozin presented at the American Diabetes Association’s 2020 congress, along with the implications for primary care.

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

Stay up to date...

Subscribe to our weekly email update with links to our latest videos.

Before you go...

Would you like to subscribe to our weekly email update containing links to the latest videos on GPnotebook TV?

We use anonymous cookies to generate usage statistics. Please click here to find out more.